Univercells SA, a company that designs single-use cost-efficient bioprocess solutions to open the next chapter in biomanufacturing, has announced that it has closed an equity investment of €3 million with Takeda Pharmaceutical Company Limited through its strategic venture arm, Takeda Ventures, Inc.
The companies will launch a development programme to tailor Univercells’ continuous integrated manufacturing methods and integrate them into the Takeda vaccines production platform.
“Partnering with Takeda is a strong sign that we are heading in the right direction. We are excited to collaborate with a pioneering global player focused on helping people above all else,” said Hugues Bultot, CEO of Univercells.
“Equal access to health around the globe is critical and we believe this comes through decentralized production, which is the biggest challenge in this new era of biomanufacturing,” said Jose Castillo, CTO of Univercells.
“Takeda is committed to making its vaccines available to people in need, wherever they may live. Reducing production costs while maintaining the highest levels of quality is an important part of our access strategy, and manufacturing science plays a critical role,” said Dr Rajeev Venkayya, President of Takeda’s Vaccine Business Unit.